The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Cyclofem     [(6S,8R,9S,10R,13S,14S,17R)- 17-ethanoyl-6...

Synonyms: Cycloprovera, HRP112, HRP 112, LS-118625, AC1L1Y6G, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Cyclofem

  • There were insignificant changes in the systolic and diastolic blood pressure values recorded at follow-up; only one Cyclofem user developed systemic hypertension (160/100 mm Hg) after 6 months of use and was discontinued for that reason [1].
  • The most frequently cited problems among Cyclofem users included breast tenderness, abdominal pain, and dysmenorrhea; yet a third of these women opted to stay on Cyclofem at the end of the study [2].
  • In conclusion, long-term administration of the injectable contraceptive Cyclofem did not produce adverse alterations in the endometrium as hyperplasia [3].
  • Data based on the trial (March 1990-February 1992) indicate that the Cyclofem women complained of dizziness, nausea, bleeding problems, migraine, vomiting, amenorrhea, allergies and hypertension during the use of Cyclofem [4].

High impact information on Cyclofem

  • Main reasons for discontinuation included difficulty making clinic visits (45.1% for Cyclofem vs. 40% for Depo-Provera), menstrual changes (14.1% vs. 12.5%) and nonmenstrual problems (15.5% vs. 12.5%) [5].
  • There was significant interindividual variation in the pharmacokinetics of MPA after intramuscular injection of Cyclofem [6].
  • This would include providing training and updated technical guidelines concerning both Cyclofem and other contraceptives to providers, with an emphasis on technical issues including contraceptive indications and contraindications, re-injection time frames, maintenance of asepsis and the management of side-effects [7].
  • A statistically significant decrease (P less than 0.01) occurred in HDL-cholesterol and total serum protein values and a statistically significant increase (P less than 0.01) was observed in hematocrit value of Cycloprovera users only [8].
  • The dose of MPA in the monthly injectable CycloProvera could be substantially reduced without loss of effectiveness [9].

Biological context of Cyclofem


Associations of Cyclofem with other chemical compounds


Analytical, diagnostic and therapeutic context of Cyclofem


  1. Once-a-month injectable contraceptives, Cyclofem and Mesigyna, in Egypt. Efficacy, causes of discontinuation, and side effects. Hassan, E.O., el-Nahal, N., el-Hussinie, M. Contraception. (1999) [Pubmed]
  2. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea. Piya-Anant, M., Koetsawang, S., Patrasupapong, N., Dinchuen, P., d'Arcangues, C., Piaggio, G., Pinol, A. Contraception. (1998) [Pubmed]
  3. Endometrial histology in long-term users of the once-a-month injectable contraceptive Cyclofem. Bahamondes, L., Maradiegue, E., Diaz, J., Trelles, J., Escanhoela, C., Petta, C., Arce, X.E. Advances in contraception : the official journal of the Society for the Advancement of Contraception. (1999) [Pubmed]
  4. Introductory trial of the once-a-month injectable contraceptive, Cyclofem, in Indonesia. Pandi, S.P., Hadjar, L.N., Prihyugiharto, T. Advances in contraception : the official journal of the Society for the Advancement of Contraception. (1993) [Pubmed]
  5. Comparative acceptability of combined and progestin-only injectable contraceptives in Kenya. Ruminjo, J.K., Sekadde-Kigondu, C.B., Karanja, J.G., Rivera, R., Nasution, M., Nutley, T. Contraception. (2005) [Pubmed]
  6. Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. Zhou, X.F., Shao, Q.X., Han, X.J., Weng, L.J., Sang, G.W. Contraception. (1998) [Pubmed]
  7. Maintaining technical quality of care in the introduction of Cyclofem in a national family planning program: findings from Indonesia. Lubis, F., Fajans, P., Simmons, R. Contraception. (1994) [Pubmed]
  8. Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters. Haiba, N.A., el-Habashy, M.A., Said, S.A., Darwish, E.A., Abdel-Sayed, W.S., Nayel, S.E. Contraception. (1989) [Pubmed]
  9. Pharmacokinetic study of different doses of Depo Provera. Fotherby, K., Koetsawang, S., Mathrubutham, M. Contraception. (1980) [Pubmed]
  10. Return of fertility after discontinuation of the once-a-month injectable contraceptive Cyclofem. Bahamondes, L., Lavín, P., Ojeda, G., Petta, C., Diaz, J., Maradiegue, E., Monteiro, I. Contraception. (1997) [Pubmed]
  11. Introduction of cyclofem once-a-month injectable contraceptive in Mexico. Garza-Flores, J., Moraks del Olmo, A., Fuziwara, J.L., Figueroa, J.G., Alonso, A., Monroy, J., Perez, M., Urbina-Fuentes, M., Guevara, S.J., Cedeno, E., Barrios, R., Ferman, J.J., Medina, L.M., Velazquez, E., Perez-Palacios, G. Contraception. (1998) [Pubmed]
  12. Self-administration with UniJect of the once-a-month injectable contraceptive Cyclofem. Bahamondes, L., Marchi, N.M., Nakagava, H.M., de Melo, M.L., Cristofoletti, M.d.e. .L., Pellini, E., Scozzafave, R.H., Petta, C. Contraception. (1997) [Pubmed]
  13. Once-a-month injectable contraceptives: efficacy and reasons for discontinuation. Koetsawang, S. Contraception. (1994) [Pubmed]
WikiGenes - Universities